MedPath

A open label, randomized, controled trial to assess the utility of Pitavastatin for patients with type2 diabetes and obesity in Matsuyama Shimin Hospital.

Not Applicable
Recruiting
Conditions
Type 2 diabetic patients with hyperlipidemia
Registration Number
JPRN-UMIN000007024
Lead Sponsor
MATSUYAMA SHIMIN HOSPITA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with insulin. 2) Patients requiring hospitalization to attain glycemic control. 3) Patients who have hypersensitivity to LIVALO tablet. 4) Patients who have severe liver dysfunction or biliary atresia. 5)Patients who are being treated with cyclosporine. 6) Pregnant women, women suspected of being pregnant, or lactating women. 7) Patients judged inadequate to participate in this study by their physician.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
change about HbA1c
Secondary Outcome Measures
NameTimeMethod
1)change in following laboratory data 1.fasting Glucose 2.HOMA-IR 3.adiponectin 4.hs-CRP 5.visceral fat,hepatic CT 6.AST,ALT 7.serum lipids (TC,LDL-C,HDL-C,TG) 8.Apoprotein (ApoA-1,ApoB,ApoE) 2) Relationship of following laboratory data 1. Relationship of change about HbA1c and change about each laboratory data 2. Relationship BMI and change about each laboratory data 3. Relationship of change about serum lipids(LDL-C,HDL-C,TG),Apoprotein(ApoA-1,ApoB,ApoE)and change about each laboratory data 4. Relationship of change about ALT,AST and change about each laboratory data 5. Relationship of change about visceral fat,hepatic CT and change about each laboratory data
© Copyright 2025. All Rights Reserved by MedPath